Trials / Terminated
TerminatedNCT00100685
Study of M200 (Volociximab) in Patients With Metastatic Renal Cell Carcinoma (RCC)
Phase 2 Open-Label Study of Volociximab (M200) in Patients With Metastatic Renal Cell Carcinoma
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 48 (actual)
- Sponsor
- Abbott · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This clinical trial is being conducted to determine tumor response and preliminary safety of a monoclonal antibody that specifically binds to a cell surface receptor (α5β1 integrin) and is required for the establishment of new blood vessels during tumor growth, a process known as angiogenesis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Volociximab (anti-α5β1 integrin monoclonal antibody) | Volociximab intravenously (Cohort 1: 10 mg/kg every other week or Cohort 2: 15 mg/kg once a week) for up to 104 weeks or until disease progression, whichever occurs first. |
Timeline
- Start date
- 2005-01-01
- Primary completion
- 2007-12-01
- Completion
- 2007-12-01
- First posted
- 2005-01-05
- Last updated
- 2012-04-27
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00100685. Inclusion in this directory is not an endorsement.